ARTICLE | Clinical News
Glivec: Phase I data; NDA under review
April 9, 2001 7:00 AM UTC
In a dose-escalating U.S. Phase I trial of Glivec in 83 patients with chronic phase CML who were refractory to interferon-alfa treatment, Glivec was well tolerated with adverse events including nausea...